acriflavine / Johns Hopkins University - LARVOL DELTA

Codelivery Material System of Polymer Microfiber Structures for Synergistic Localized Therapy of Glioblastoma. (PubMed, ACS Biomater Sci Eng) - "We report on the synergistic effect of the FDA-approved anti-GBM drug (temozolomide) and inhibitors (acriflavine, PT2385) of hypoxia-inducible factors (HIFs) embedded into coaxial fiber membranes (NanoMesh). In vitro cytotoxicity has been evaluated for various glioma cell lines, and synergistic drug combinations have been identified. Preliminary animal studies with the three-drug-loaded NanoMesh indicate a significant improvement of median survival of >50 days and long-term (>120 days) survival rate of 40%, indicating the potential of this material platform as a translatable local GBM therapy."

Journal • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor

Targeting hypoxia-inducible factors with 32-134D safely and effectively treats diabetic eye disease in mice. (PubMed, J Clin Invest) - "However, while the HIF-inhibitor acriflavine prevented retinal vascular hyperpermeability in diabetic mice for several months following a single intraocular injection, accumulation of acriflavine in the retina resulted in retinal toxicity over time, raising concerns for its use in patients...Intraocular administration of 32-134D prevented retinal neovascularization and vascular hyperpermeability in mice. These results provide the foundation for clinical studies assessing 32-134D for the treatment of patients with diabetic eye disease."

Journal • Preclinical • Age-related Macular Degeneration • Diabetes • Diabetic Retinopathy • Metabolic Disorders • Ophthalmology • Retinal Disorders